Indacaterol, A Novel Once Daily Inhaled β2-Adrenoreceptor Agonist
Jorge Roig*, 1, Rosana Hernando2, Ramon Mora
Identifiers and Pagination:Year: 2009
First Page: 27
Last Page: 30
Publisher ID: TORMJ-3-27
Article History:Received Date: 29/1/2009
Revision Received Date: 3/2/2009
Acceptance Date: 13/2/2009
Electronic publication date: 12/3/2009
Collection year: 2009
open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
In this article we will review the role of long acting β2-adrenoreceptor agonists and long-acting muscarinic agents in the management of airflow obstruction. We will then focus our attention on indacaterol, one of the new once daily inhaled β2-adrenoreceptor agonists. Pharmacologically this drug is a nearly full β2-agonist without loss of efficacy after prolonged administration. We will also discuss its dosing, safety and tolerability.